NEWS CENTER

RainMed Medical and SINOMED Signed a Strategic Collaboration Agreement to Jointly Promote the Development of Precision Medicine

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2023-03-03 10:01
  • Views:

(Summary description)On February 28, 2023, RainMed Medical (stock code: 2297.HK) and SINOMED (stock code: 688108.SH) held a strategic collaboration agreement signing ceremony in Beijing. Mr. Yunfei Huo, chairman of the board, executive director and CEO of RainMed Medical, and Mr. Jianhua Sun, chairman and CEO of SINOMED, signed the agreement on behalf of both parties. Professor Yong Huo from Peking University First Hospital, and Professor Yunlong Huo, Co-founding shareholder of RainMed Medical and professor of School of Life Science and Biotechnology of Shanghai Jiao Tong University, also attended the meeting.

RainMed Medical and SINOMED Signed a Strategic Collaboration Agreement to Jointly Promote the Development of Precision Medicine

(Summary description)On February 28, 2023, RainMed Medical (stock code: 2297.HK) and SINOMED (stock code: 688108.SH) held a strategic collaboration agreement signing ceremony in Beijing. Mr. Yunfei Huo, chairman of the board, executive director and CEO of RainMed Medical, and Mr. Jianhua Sun, chairman and CEO of SINOMED, signed the agreement on behalf of both parties. Professor Yong Huo from Peking University First Hospital, and Professor Yunlong Huo, Co-founding shareholder of RainMed Medical and professor of School of Life Science and Biotechnology of Shanghai Jiao Tong University, also attended the meeting.

  • Categories:News Center
  • Author:
  • Origin:
  • Time of issue:2023-03-03 10:01
  • Views:
Information

On February 28, 2023, RainMed Medical (stock code: 2297.HK) and SINOMED (stock code: 688108.SH) held a strategic collaboration agreement signing ceremony in Beijing. Mr. Yunfei Huo, chairman of the board, executive director and CEO of RainMed Medical, and Mr. Jianhua Sun, chairman and CEO of SINOMED, signed the agreement on behalf of both parties. Professor Yong Huo from Peking University First Hospital, and Professor Yunlong Huo, Co-founding shareholder of RainMed Medical and professor of School of Life Science and Biotechnology of Shanghai Jiao Tong University, also attended the meeting.

 

The strong alliance between a domestic high-tech Hong Kong-listed company in the field of vascular precision diagnosis and treatment and an international high-end interventional medical device A-share company listed on SSE STAR MARKET will definitely give full play to the advantages of both parties in research and development as well as academics and marketing. In addition, it will strengthen cardiovascular research and innovation capabilities, promote large-scale clinical research at home and abroad, enhance product popularity, expand marketing network, and make precision medical achievements benefit patients with cardiovascular diseases around the world.

 

 

RainMed Medical is a national high-tech enterprise. Based on global market, it focuses on scientific and technological innovation, adheres to independent R&D and the purpose of "Targeted Medical Services for People's Health". Now it has created a series of industry-leading functional diagnostic products which have been widely recognized by the clinical research and built a comprehensive marketing network at home and abroad, bringing revolutionary diagnosis and treatment products to patients with vascular diseases around the world. SINOMED is a leading enterprise in the field of cardiovascular and cerebrovascular disease treatment. After years of hard work, it has created a rich product matrix and a well-developed marketing network. Its commercialized products have been exported to China, Southeast Asia, South America and other regions. At present, it is the first and only domestic drug stent enterprise approved to carry out large-scale confirmatory clinical studies before marketing in the United States and Japan. The strategic cooperation between RainMed Medical and SINOMED will complement each other's advantages and share resources to promote the development of precision medicine to a new height!

 

Professor Yong Huo noted that RainMed Medical and SINOMED are both forward-looking and leading high-tech medical device companies in the field of cardiovascular disease. As a high-quality listed company with excellent innovation ability and scientific research, the strategic partnership between RainMed Medical and SINOMED is really exciting. He expressed the hope that it will create greater industrial value, produce fruitful scientific research results, and eventually reach the effect of 1+1 > 2. At the same time, he also hope that the two enterprises can make persistent efforts to develop innovative products with more unique clinical value, promote the rapid development of the industry, and make contributions to the prevention and treatment of cardiovascular diseases in China.

 

Prof. Yunlong Huo pointed out that RainMed Medical has been rooted in scientific research and innovation since its establishment, and it is committed to producing world's leading vascular interventional surgery robot. After eight years hard work, RainMed finally developed and launched caFFR system with the highest accuracy in China and the first caIMR system in the world. These two products are important components of RainMeds robot diagnostic system, which is more convenient and efficient than guidewire-derived FFR and IMR. As a leading enterprise in the field of cardiovascular disease treatment, SINOMED has a solid scientific research and academic foundation in the industry. We hope that this cooperation can promote the upgrading of medical technology, the progress of clinical scientific research, and play the exemplary role of the head enterprise.

 

President of SINOMED Mr. Jianhua Sun said that SINOMED aims to build a world-renowned Chinese innovative brand by developing high-quality medical products, enhancing the influence of "Made in China" in the international scope. To this end, SINOMED continues to expand its product matrix, launch a series of innovative products, and complete a number of large-scale clinical research projects worldwide. RainMeds caFFR system is capable of performing preoperative diagnosis, intraoperative guidance and postoperative evaluation for coronary interventional surgery. The combination of RainMeds caFFR system and SINOMEDs stent will surely develop a better scientific diagnosis and treatment plan for the clinic. We believe that the cooperation between the two companies will certainly enhance the development of the industry and benefit thousands of patients with cardiovascular diseases.

 

Ms. Yundi Feng, medical director of RainMed; Mr. Kefu Xia, director of International Marketing Department of RainMed; Ms. Rei Mu, vice sales director of RainMed; Mr. Kai Huang, director and secretary of the board of directors of SINOMED, and Mr. Xiangfei Miao, director of business development and international marketing of SINOMED, also attended the signing ceremony of the strategic cooperation.

CONTACT US

0512-62622215

Address: Building 31, Northeast District, Nano City, No. 99 Jinji Lake Avenue, Suzhou industrial park

这是描述信息

WeChat public account

这是描述信息

Recruitment QR Code

We use cookies to improve our site and your shopping experience. By continuing to browse our site you accept our cookie policy. Find out more
close

Page Copyright© 2021- Suzhou Rainmed Medical Technology Co., Ltd.  苏公网安备32059002003601号  (苏)-非经营性-2021-0149